Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks

Structure Therapeutics Inc.

Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.
OLE study shows continued weight loss up to 16.2% at 56 weeks; no plateau observed.
Lower 2.5 mg starting dose improves tolerability; AE-related discontinuations 2-3.4% in interim OLE / body composition studies.
End-of-Phase 2 meeting with FDA scheduled Q2 2026; Phase 3 initiation on track for 2H 2026.
No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation across >625 participants.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.